202 related articles for article (PubMed ID: 9151680)
41. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
42. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
Aguirre-Ghiso JA; Estrada Y; Liu D; Ossowski L
Cancer Res; 2003 Apr; 63(7):1684-95. PubMed ID: 12670923
[TBL] [Abstract][Full Text] [Related]
43. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
[TBL] [Abstract][Full Text] [Related]
44. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
45. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
46. Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Krishnamoorthy B; Darnay B; Aggarwal B; Dinh DH; Kouraklis G; Olivero WC; Gujrati M; Rao JS
Clin Cancer Res; 2001 Dec; 7(12):4195-201. PubMed ID: 11751520
[TBL] [Abstract][Full Text] [Related]
47. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
[TBL] [Abstract][Full Text] [Related]
48. Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach.
Ahmed N; Oliva K; Wang Y; Quinn M; Rice G
Proteomics; 2003 Mar; 3(3):288-98. PubMed ID: 12627382
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model.
Wang Y; Liang X; Wu S; Murrell GA; Doe WF
Int J Cancer; 2001 Apr; 92(2):257-62. PubMed ID: 11291054
[TBL] [Abstract][Full Text] [Related]
50. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Rabbani SA; Xing RH
Int J Oncol; 1998 Apr; 12(4):911-20. PubMed ID: 9499455
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.
Rao JS; Gondi C; Chetty C; Chittivelu S; Joseph PA; Lakka SS
Mol Cancer Ther; 2005 Sep; 4(9):1399-408. PubMed ID: 16170032
[TBL] [Abstract][Full Text] [Related]
52. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.
Mohanam S; Gladson CL; Rao CN; Rao JS
Front Biosci; 1999 Feb; 4():D178-87. PubMed ID: 9989951
[TBL] [Abstract][Full Text] [Related]
53. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
54. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ahmed N; Riley C; Oliva K; Rice G; Quinn M
Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
[TBL] [Abstract][Full Text] [Related]
55. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
56. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric-cancer cell lines correlates with their invasiveness and tumorigenicity.
Park IK; Kim BJ; Goh YJ; Lyu MA; Park CG; Hwang ES; Kook YH
Int J Cancer; 1997 May; 71(5):867-73. PubMed ID: 9180158
[TBL] [Abstract][Full Text] [Related]
57. Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Adachi Y; Lakka SS; Chandrasekar N; Yanamandra N; Gondi CS; Mohanam S; Dinh DH; Olivero WC; Gujrati M; Tamiya T; Ohmoto T; Kouraklis G; Aggarwal B; Rao JS
J Biol Chem; 2001 Dec; 276(50):47171-7. PubMed ID: 11572856
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
[TBL] [Abstract][Full Text] [Related]
59. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
60. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Borgfeldt C; Hansson SR; Gustavsson B; Måsbäck A; Casslén B
Int J Cancer; 2001 May; 92(4):497-502. PubMed ID: 11304683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
